Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide.
The L5178Y (LY) murine lymphoma subline, LY-R, is more radioresistant and more sensitive to camptothecin (CPT, inhibitor of topisomerase I) than the second subline used in our investigation, LY-S. Post-irradiation treatment with 3 microM CPT enhanced the radiosensitivity of LY-S cells (D0 decrease from 0.52 to 0.34 Gy), but did not change it in LY-R cells. Treatment with 2 mM benzamide [BZ, inhibitor of poly (ADP-ribosylation)] before x-rays and CPT increased the radiosensitivity of LY-R cells (D0 decrease from 1.15 to 0.52) without further modification of radiosensitivity of LY-S cells. Activity of topoisomerase I was diminished 10 min after x-irradiation (5 Gy) in LY-S, but not in LY-R cells. The data on DNA damage (fluorescent halo or comet assays) showed that the ultimate fate of the cells did not depend on the DNA damage pattern estimated immediately after treatment (e.g. the damage was greater in x-rays plus CPT than in BZ plus x-rays plus CPT treated LY-R cells, although the radiosensitivity was less). Aphidicolin (inhibitor of DNA polymerases alpha and delta) applied concomitantly with CPT in cells not pretreated with BZ prevented the increase in DNA damage in LY-R cells, but was without effect in LY-S cells. Taking into account the differential inhibition by x-rays of DNA synthesis in LY sublines and its reversion by BZ in LY-S but not in LY-R cells, we conclude that the pattern of DNA damage observed by the methods applied depended on the status of DNA replication.
Gradzka
I
I
Institute of Nuclear Chemistry and Technology, Department of Radiobiology, Warszawa, Poland.
Iwaneńko
T
T
Kruszewski
M
M
Szumiel
I
I
Kapiszewska
M
M
Lange
C S
CS
Afanasjev
G
G
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D002166:Camptothecin / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004249:DNA Damage; D004261:DNA Replication; D007940:Leukemia L5178 / Q000473:pathology / Q000628:therapy; D051379:Mice; D011064:Poly Adenosine Diphosphate Ribose / Q000378:metabolism; D011836:Radiation Tolerance; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured; D014965:X-Rays
D000972:Antineoplastic Agents, Phytogenic; D001549:Benzamides; D059004:Topoisomerase I Inhibitors; D011064:Poly Adenosine Diphosphate Ribose; C037689:benzamide; D002166:Camptothecin